Medicine & Life Sciences
Multiple Myeloma
100%
Cell Transplantation
72%
Hematopoietic Stem Cell Transplantation
58%
Transplants
53%
Lymphoma, Large B-Cell, Diffuse
45%
Acute Myeloid Leukemia
37%
Lenalidomide
35%
Chimeric Antigen Receptors
34%
Survival
33%
ponatinib
31%
Allogeneic Cells
30%
Protein-Tyrosine Kinases
27%
Maintenance
26%
Cell- and Tissue-Based Therapy
24%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23%
Stem Cells
23%
Hematopoietic Stem Cells
22%
Progression-Free Survival
21%
venetoclax
20%
Stem Cell Transplantation
19%
Retrospective Studies
19%
Hemophagocytic Lymphohistiocytosis
18%
Transplantation
18%
Azacitidine
18%
GATA2 Deficiency
17%
Multicenter Studies
17%
B-Cell Lymphoma
16%
Premature Aging
16%
bosutinib
16%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
16%
T-Lymphocytes
15%
Autologous Transplantation
15%
Therapeutics
15%
Dasatinib
14%
Residual Neoplasm
14%
Neoplasms
14%
Plasma Cells
14%
Blood Vessels
14%
Recurrence
13%
Autografts
13%
Pandemics
13%
Imatinib Mesylate
12%
midostaurin
12%
Non-Hodgkin's Lymphoma
11%
PCI 32765
11%
Vascular Endothelial Growth Factor A
11%
Lymphoma
10%
treosulfan
10%
Drug Therapy
10%
eltrombopag
10%